Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Zunino

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Expert Opinion on Investigational Drugs|March 12, 2004
Camptothecins in clinical developmentFranco Zunino, Graziella Pratesi
Neoplasia (New York, N.Y.)|June 3, 2008
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosisValentina Zuco, Franco Zunino
Methods in Molecular Medicine|May 25, 2005
Overview of tumor cell chemoresistance mechanismsLaura Gatti, Franco Zunino
Topics in Current Chemistry|April 23, 2013
Molecular mechanisms of anthracycline activityGiovanni Luca Beretta, Franco Zunino
Biochemical Pharmacology|June 2, 2007
Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activityGiovanni Luca Beretta, Franco Zunino
Biochemical Pharmacology|June 16, 2015
Perspectives in the development of hybrid bifunctional antitumour agentsLoana Musso, Sabrina Dallavalle, Franco Zunino
Cancer Letters|January 1, 2010
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968Valentina Zuco, Valentina Benedetti, Franco Zunino
Biochemical Pharmacology|June 26, 2012
Development and therapeutic impact of HDAC6-selective inhibitorsSabrina Dallavalle, Claudio Pisano, Franco Zunino
Expert Opinion on Therapeutic Targets|September 11, 2008
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitorsGiovanni Luca Beretta, Paola Perego, Franco Zunino
Cement & Concrete Composites|June 9, 2018
Reducing setting time of blended cement paste containing high-SO<sub>3</sub> fly ash (HSFA) using chemical/physical accelerators and by fly ash pre-washingFranco Zunino, Dale P Bentz, Javier Castro
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Expert Opinion on Investigational Drugs|March 12, 2004
Camptothecins in clinical developmentFranco Zunino, Graziella Pratesi
Neoplasia (New York, N.Y.)|June 3, 2008
Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosisValentina Zuco, Franco Zunino
Methods in Molecular Medicine|May 25, 2005
Overview of tumor cell chemoresistance mechanismsLaura Gatti, Franco Zunino
Topics in Current Chemistry|April 23, 2013
Molecular mechanisms of anthracycline activityGiovanni Luca Beretta, Franco Zunino
Biochemical Pharmacology|June 2, 2007
Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activityGiovanni Luca Beretta, Franco Zunino
Biochemical Pharmacology|June 16, 2015
Perspectives in the development of hybrid bifunctional antitumour agentsLoana Musso, Sabrina Dallavalle, Franco Zunino
Cancer Letters|January 1, 2010
ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968Valentina Zuco, Valentina Benedetti, Franco Zunino
Biochemical Pharmacology|June 26, 2012
Development and therapeutic impact of HDAC6-selective inhibitorsSabrina Dallavalle, Claudio Pisano, Franco Zunino
Expert Opinion on Therapeutic Targets|September 11, 2008
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitorsGiovanni Luca Beretta, Paola Perego, Franco Zunino
Cement & Concrete Composites|June 9, 2018
Reducing setting time of blended cement paste containing high-SO<sub>3</sub> fly ash (HSFA) using chemical/physical accelerators and by fly ash pre-washingFranco Zunino, Dale P Bentz, Javier Castro
Pageof 15